Shared Resources
Viral Vector Core Facilities:
A non-profit organization dedicated to making it easier for scientists to share plasmids.
Production: Adenovirus; Retrovirus (MoMLV); Lentivirus - HIV (VSVG, LCMV, RRV, Ebola, Marburg, Mokola, Rabies glycoprotein, RD114 pseudotypes).
Production: Adeno-Associated Virus (AAV) and Lentivirus (LV) vectors for early phase clinical trials. Pharm-tox GLP and GMP grade (FDA, MHRA and EMA compliant).
Production: Retrovirus; Lentivirus; AAV; Adenovirus; Foamy virus; Master cell banks; Mater viral banks; Working cell banks (Research, preclinical and GMP-grade).
Production: Retrovirus; Lentivirus (clinical grade production services available).
Production: Cell and/or vector manufacture in the realms of adoptive immunotherapies, vaccines, and stem cell-based therapies.
Production: Adenovirus, Adeno-Associated Virus (AAV), Cytomegalovirus (CMV) and Simian Immunodeficiency Virus (SIV) stocks for Non-Human Primate Studies; Tissue Processing and Virus Diagnostics; Specific Pathogen Free (SPF) Colony Viral Agents and Diagnostics
Production: Adenovirus; AAV (1, 2, 5, 6, 8, 9) and GMP clinical grade vector production capability.
Production: Lentivirus - HIV, EIAV; Pseudotypes: VSVG, ALSV EnvA, ALSV EnvB, Rabies glycoprotein; Retrovirus; AAV (1, 2, 3, 4, 5, 6, 8, 9, rh10).
Gene Vector and Virus Core centralizes the process of producing and distributing viral vectors and cDNA plasmids. High throughput custom AAV production with available stock virus
Production: AAV
Production: Adenovirus; MoMLV; AAV (1, 2, 4, 5, 8); Lentivirus - HIV, FIV (numerous pseudotypes).
Production: Adenovirus
Retrovirus: MoMLV; Lentivirus - FIV, HIV; AAV
Production: Adenovirus; Lentivirus; AAV (pre-clinical and clinical grade production available).
Production: Adenovirus; Lentivirus - HIV (VSVG, MuLV, LCMB, Mokola, Ebola pseudotypes); AAV (1, 2, 5, 6, 7, 8, 9, and rh10).
Production: Adenovirus; Lentivirus
Cell Processing Facilities:
A non-profit organization dedicated to making it easier for scientists to share plasmids.
Production: Hematopoietic Progenitor Cells, Donor Leukocytes for immunotherapy, Antigen-specific T cells, T cells bearing chimeric antigen receptors, Pancreatic Islets, Liver Progenitor Cells, Cells for Cardiac and Brain injury repair, Tumor Vaccines, Transduced and transfected cells.
CHCT only facilitates the development of new cellular therapies for departments and affiliated institutions of Harvard Medical School. If you are a member of this community, please contact CHCT for more information.
Services: Enrichment, depletion, selection and culture of a wide variety of primary human cell types including: hematopoietic progenitors and stem cells, mesenchymal stem and progenitor cells, tumors, hematopoietic populations (erythroid, myeloid and B- and T-lymphoid populations). Ex-vivo genetic modification (transduction).
Production: Adeno-Associated Virus (AAV) and Lentivirus (LV) vectors for early phase clinical trials. Pharm-tox GLP and GMP grade (FDA, MHRA and EMA compliant).
Production: Cell and/or vector manufacture in the realms of adoptive immunotherapies, vaccines, and stem cell-based therapies.
Production: manufacturing of hematopoietic stem cells derived from peripheral blood, umbilical cord blood, and bone marrow; isolation and purification of allogeneic and autologous pancreatic islet cells; isolation and expansion of CD4/CD25 regulatory T cells (UCB and PB)
Services: Stem Cell Transplant, Regenerative Medicine, Umbilical Cord Blood Program, and Quality Assurance
Production: mammalian cells for use in cell therapy applications, ex-vivo gene therapy, or production of master and working cell banks for biotherapeutics production.